Methotrexate Failure, Latent TB, and a Patient Who Wants 'a Pill'

Methotrexate must stop now, not be dose-reduced. A FIB-4 of 2.9 sits above the 2.67 high-risk cut-off, and it is compounded by three years of exposure, daily alcohol, thrombocytopenia (118), and transaminases roughly twice normal. eGFR 38 independently contraindicates methotrexate (avoid below 45 because of accumulation and myelosuppression). Do not simply monitor - refer for elastography or hepatology assessment.

Sequence:

1. Treat latent TB first. Four months of rifampin or nine months of isoniazid. Rifampin has no meaningful interaction with the biologics in question. Insurer documentation must precede the biologic.
2. Secukinumab next. No renal dose adjustment, no TB reactivation signal, and rapid onset. Screen for inflammatory bowel disease and hepatitis B before starting; counsel about candidiasis and the paradoxical eczematous eruption.
3. Adalimumab as an alternative, but it carries the greatest reactivation risk and higher immunogenicity in a patient who may be intermittently adherent.
4. Apremilast is the pill he wants, but it is last-line here: PASI 75 rates are roughly 30% versus 60–80% for the biologics, and at eGFR 38 he still needs the usual 30 mg twice daily (once daily only below 30).

Do not start any biologic while LTBI is untreated - that ordering is the crux of the question.

Why deferral is wrong. His QuantiFERON is positive with a normal chest film, i.e., latent infection. The absolute reactivation risk is highest with TNF inhibitors and lower with IL-17A inhibitors, but every major guideline still requires LTBI therapy before a biologic, and the insurer in this scenario has made it a condition of dispensing. "Later" also means a patient who is unreliable about monthly visits may never complete it.

Practical compromise: start LTBI therapy and apremilast concurrently as a bridge if he needs visible progress, while being explicit that apremilast is unlikely to control PASI 18.

Secukinumab monitoring:

• Baseline: CBC, hepatic panel, hepatitis B and C serology, HIV per local guideline; repeat TB testing annually if ongoing exposure risk.
• No renal adjustment needed at eGFR 38.
• Efficacy check at 12–16 weeks using PASI/BSA; if <50% improvement, reassess adherence and diagnosis rather than reflexively escalating.
• Safety checks: oral/genital candidiasis, new diarrhoea or rectal bleeding (IBD), and injection-site reactions.
• Address alcohol directly - it drives his FIB-4 and will confound any future liver monitoring.

Adherence is a legitimate selection criterion, not merely a counselling problem, and it should push the plan toward options with the fewest visits and the most forgiving dosing intervals.

• Secukinumab wins on visit burden: induction at weeks 0, 1, 2, 3, 4 then monthly maintenance, all self-injected after training. He does not need to come to clinic monthly; he needs to attend for labs at baseline and periodically.
• Adalimumab every other week is equally self-administered but has higher immunogenicity and more consequence if doses are skipped.
• Apremilast is oral and visit-light but less effective; it also causes diarrhoea, nausea, and weight loss, which he may not tolerate.
• Narrowband UVB, which he has never tried, is an option on paper but requires three visits weekly - precisely the burden he is rejecting. Home phototherapy only helps if his insurer covers it.

Frame this as shared decision-making: name the trade-off between convenience and clearance, document his preference, and set a review point at 12 weeks. Also flag that alcohol reduction is part of the plan regardless of which systemic is chosen.